NO20075490L - Fremgangsmate for behandling av prostatasykdommer basert pa lokal avlevering av aktive substanser - Google Patents
Fremgangsmate for behandling av prostatasykdommer basert pa lokal avlevering av aktive substanserInfo
- Publication number
- NO20075490L NO20075490L NO20075490A NO20075490A NO20075490L NO 20075490 L NO20075490 L NO 20075490L NO 20075490 A NO20075490 A NO 20075490A NO 20075490 A NO20075490 A NO 20075490A NO 20075490 L NO20075490 L NO 20075490L
- Authority
- NO
- Norway
- Prior art keywords
- calcium
- barium
- magnesium
- active substances
- hydrated
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 208000017497 prostate disease Diseases 0.000 title 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 abstract 4
- 239000000919 ceramic Substances 0.000 abstract 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 abstract 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 abstract 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 abstract 2
- 230000000887 hydrating effect Effects 0.000 abstract 2
- 210000002307 prostate Anatomy 0.000 abstract 2
- OYLGJCQECKOTOL-UHFFFAOYSA-L barium fluoride Chemical compound [F-].[F-].[Ba+2] OYLGJCQECKOTOL-UHFFFAOYSA-L 0.000 abstract 1
- 229910001632 barium fluoride Inorganic materials 0.000 abstract 1
- 229910052916 barium silicate Inorganic materials 0.000 abstract 1
- HMOQPOVBDRFNIU-UHFFFAOYSA-N barium(2+);dioxido(oxo)silane Chemical compound [Ba+2].[O-][Si]([O-])=O HMOQPOVBDRFNIU-UHFFFAOYSA-N 0.000 abstract 1
- WAKZZMMCDILMEF-UHFFFAOYSA-H barium(2+);diphosphate Chemical compound [Ba+2].[Ba+2].[Ba+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O WAKZZMMCDILMEF-UHFFFAOYSA-H 0.000 abstract 1
- AYJRCSIUFZENHW-DEQYMQKBSA-L barium(2+);oxomethanediolate Chemical compound [Ba+2].[O-][14C]([O-])=O AYJRCSIUFZENHW-DEQYMQKBSA-L 0.000 abstract 1
- 229910000019 calcium carbonate Inorganic materials 0.000 abstract 1
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 abstract 1
- 229910001634 calcium fluoride Inorganic materials 0.000 abstract 1
- 239000001506 calcium phosphate Substances 0.000 abstract 1
- 229910000389 calcium phosphate Inorganic materials 0.000 abstract 1
- 235000011010 calcium phosphates Nutrition 0.000 abstract 1
- 239000000378 calcium silicate Substances 0.000 abstract 1
- 229910052918 calcium silicate Inorganic materials 0.000 abstract 1
- 235000012241 calcium silicate Nutrition 0.000 abstract 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 abstract 1
- 239000001095 magnesium carbonate Substances 0.000 abstract 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 abstract 1
- 235000014380 magnesium carbonate Nutrition 0.000 abstract 1
- ORUIBWPALBXDOA-UHFFFAOYSA-L magnesium fluoride Chemical compound [F-].[F-].[Mg+2] ORUIBWPALBXDOA-UHFFFAOYSA-L 0.000 abstract 1
- 229910001635 magnesium fluoride Inorganic materials 0.000 abstract 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 abstract 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 abstract 1
- 239000004137 magnesium phosphate Substances 0.000 abstract 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 abstract 1
- 229960002261 magnesium phosphate Drugs 0.000 abstract 1
- 235000010994 magnesium phosphates Nutrition 0.000 abstract 1
- 239000000391 magnesium silicate Substances 0.000 abstract 1
- 229910052919 magnesium silicate Inorganic materials 0.000 abstract 1
- 235000019792 magnesium silicate Nutrition 0.000 abstract 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 abstract 1
- 235000019341 magnesium sulphate Nutrition 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Botany (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Fremgangsmåte for behandling av prostata relaterte sykdommer i et subjekt, fremgangsmåten som omfatter i) eventuell administrering til subjektet en initiell forsterkningsdose av en eller flere aktive substanser og/eller promedikamenter, og ii) administrering lokalt inn i prostata av en kontrollert frigjørende farmasøytisk sammensetning som omfatter en eller flere aktive substanser i en bionedbrytbar keramisk bærer. Den bionedbrytbare hydratiserende keramen kan bli valgt fra gruppen som består av ikke-hydratisert eller hydratisert kalsium sulfat, kalsium fosfat, kalsium karbonat, kalsium fluorid, kalsium silikat, magnesium sulfat, magnesium fosfat, magnesium karbonat, magnesium fluorid, magnesium silikat, barium sulfat, barium fosfat, barium karbonat, barium fluorid, barium silikat, eller blandinger derav. I en spesifikk utførelsesform, er den bionedbrytbare hydratiserende keramen ikke-hydratisert eller hydratisert kalsium sulfat.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200500452 | 2005-03-31 | ||
| PCT/EP2006/003194 WO2006103112A2 (en) | 2005-03-31 | 2006-03-31 | Method for treating prostate diseases based on local delivery of active substances |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20075490L true NO20075490L (no) | 2008-01-02 |
| NO338679B1 NO338679B1 (no) | 2016-09-26 |
Family
ID=35044589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20075490A NO338679B1 (no) | 2005-03-31 | 2007-10-30 | Kit(sett) for behandling av prostatasykdommer basert på lokal avlevering av aktive substanser |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8936809B2 (no) |
| EP (1) | EP1865924B1 (no) |
| JP (2) | JP5635231B2 (no) |
| KR (2) | KR101380402B1 (no) |
| CN (1) | CN101160116B (no) |
| AU (1) | AU2006228675B2 (no) |
| CA (1) | CA2602776C (no) |
| DK (1) | DK1865924T3 (no) |
| ES (1) | ES2557988T3 (no) |
| HU (1) | HUE026158T2 (no) |
| IL (1) | IL185690A0 (no) |
| MX (1) | MX2007011908A (no) |
| NO (1) | NO338679B1 (no) |
| PL (1) | PL1865924T3 (no) |
| RU (1) | RU2404747C2 (no) |
| WO (1) | WO2006103112A2 (no) |
| ZA (1) | ZA200708066B (no) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2557988T3 (es) * | 2005-03-31 | 2016-02-01 | Lidds Ab | Método para tratar enfermedades de próstata basado en el suministro local de principios activos |
| ES2545962T3 (es) * | 2008-11-27 | 2015-09-17 | Lidds Ab | Uso de carboximetilcelulosa para controlar la capacidad de eyección y el tiempo de solidificación de composiciones que comprenden una o más cerámicas biorreabsorbibles |
| HK1198933A1 (en) * | 2011-04-05 | 2015-06-19 | Edge Therapeutics | Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow |
| RU2519407C2 (ru) * | 2011-09-21 | 2014-06-10 | Виктор Павлович Горелов | Способ трансуретральной резекции предстательной железы, предшествующий брахитерапии рака простаты |
| GB201318862D0 (en) * | 2013-10-25 | 2013-12-11 | Glaxosmithkline Biolog Sa | Calcium fluoride compositions |
| GB201318858D0 (en) * | 2013-10-25 | 2013-12-11 | Glaxosmithkline Biolog Sa | Calcium fluoride compositions |
| CN106573133B (zh) | 2014-08-19 | 2020-03-03 | 加利福尼亚大学董事会 | 用于局部药物递送的植入物及其使用方法 |
| EP3302423B1 (en) | 2015-06-04 | 2022-05-25 | Crititech, Inc. | Particle production system and particle collection device |
| BR112018069628A2 (pt) | 2016-04-04 | 2019-02-12 | Crititech, Inc. | métodos para tratamento de tumor sólido |
| EP3615145B1 (en) | 2017-06-09 | 2024-05-15 | Crititech, Inc. | Compositions for use in the treatment of epithelial cysts by intracystic injection of antineoplastic particles |
| WO2018231908A1 (en) | 2017-06-14 | 2018-12-20 | Crititech, Inc. | Methods for treating lung disorders |
| KR20250057947A (ko) | 2017-10-03 | 2025-04-29 | 크리티테크, 인크. | 암의 치료를 위한 면역치료제의 전신 전달과 조합된 항신생물성 입자의 국소 전달 |
| US20210353570A1 (en) * | 2018-09-20 | 2021-11-18 | Biovena Science, Llc | Flutamide Microsphere-Based Arterial Embolization for Treating Prostate Disorders |
| US11911499B2 (en) | 2019-11-07 | 2024-02-27 | Resurge Therapeutics, Inc. | System and method for prostate treatment |
| US11344526B2 (en) * | 2020-03-20 | 2022-05-31 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
| JP7665645B2 (ja) | 2020-03-20 | 2025-04-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 局所的な薬物送達のための移植可能な薬物送達デバイス |
| US11338119B2 (en) * | 2020-03-20 | 2022-05-24 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
| US11173291B2 (en) * | 2020-03-20 | 2021-11-16 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
| EP4469108A1 (en) * | 2022-01-29 | 2024-12-04 | Resurge Therapeutics, Inc. | Benign prostatic hyperplasia treatment system |
| US11974979B2 (en) | 2022-01-29 | 2024-05-07 | Resurge Therapeutics, Inc. | Treatments for benign prostatic hyperplasia |
| US11957654B2 (en) | 2022-01-29 | 2024-04-16 | Resurge Therapeutics, Inc. | Treating benign prostatic hyperplasia |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474813A (en) * | 1980-10-24 | 1984-10-02 | Schering Corporation | Pharmaceutical preparations comprising flutamide |
| US5614206A (en) * | 1995-03-07 | 1997-03-25 | Wright Medical Technology, Inc. | Controlled dissolution pellet containing calcium sulfate |
| US5795330A (en) * | 1996-10-10 | 1998-08-18 | Etex Corporation | Mixing device |
| JP4260891B2 (ja) * | 1996-10-16 | 2009-04-30 | エテックス コーポレイション | 生体セラミック組成物 |
| US6391336B1 (en) * | 1997-09-22 | 2002-05-21 | Royer Biomedical, Inc. | Inorganic-polymer complexes for the controlled release of compounds including medicinals |
| US5972384A (en) * | 1997-10-01 | 1999-10-26 | University Of Maryland, Baltimore | Use of biologically active glass as a drug delivery system |
| WO2001010463A1 (en) * | 1999-08-05 | 2001-02-15 | Takeda Chemical Industries, Ltd. | Pastes with the sustained release of osteogenesis promoter |
| US6497901B1 (en) * | 2000-11-02 | 2002-12-24 | Royer Biomedical, Inc. | Resorbable matrices for delivery of bioactive compounds |
| US6645974B2 (en) * | 2001-07-31 | 2003-11-11 | Merck & Co., Inc. | Androgen receptor modulators and methods for use thereof |
| US20030147936A1 (en) | 2002-02-07 | 2003-08-07 | Velayudhan Sahadevan | Prostatic hormonal implants treatment of prostate cancer |
| CA2523178C (en) * | 2003-03-24 | 2012-10-23 | Luitpold Pharmaceuticals, Inc. | Materials and methods to potentiate cancer treatment |
| GB0307082D0 (en) * | 2003-03-27 | 2003-04-30 | Gyne Ideas Ltd | Drug delivery device and method |
| EP1608359A4 (en) * | 2003-04-03 | 2011-08-17 | Jessie L-S Au | DRUG-LOADING PARTICLES TARGETING TUMORS |
| US20040224000A1 (en) * | 2003-05-05 | 2004-11-11 | Romano Deghenghi | Implants for non-radioactive brachytherapy of hormonal-insensitive cancers |
| US8124118B2 (en) * | 2003-10-22 | 2012-02-28 | Lidds Ab | Composition comprising biodegradable hydrating ceramics for controlled drug delivery |
| ES2557988T3 (es) * | 2005-03-31 | 2016-02-01 | Lidds Ab | Método para tratar enfermedades de próstata basado en el suministro local de principios activos |
-
2006
- 2006-03-31 ES ES06724133.1T patent/ES2557988T3/es not_active Expired - Lifetime
- 2006-03-31 RU RU2007140243/14A patent/RU2404747C2/ru active
- 2006-03-31 EP EP06724133.1A patent/EP1865924B1/en not_active Expired - Lifetime
- 2006-03-31 AU AU2006228675A patent/AU2006228675B2/en not_active Ceased
- 2006-03-31 JP JP2008503447A patent/JP5635231B2/ja not_active Expired - Fee Related
- 2006-03-31 MX MX2007011908A patent/MX2007011908A/es active IP Right Grant
- 2006-03-31 HU HUE06724133A patent/HUE026158T2/en unknown
- 2006-03-31 KR KR1020077022037A patent/KR101380402B1/ko not_active Expired - Fee Related
- 2006-03-31 WO PCT/EP2006/003194 patent/WO2006103112A2/en not_active Ceased
- 2006-03-31 KR KR1020137034233A patent/KR20140014294A/ko not_active Ceased
- 2006-03-31 CN CN2006800100200A patent/CN101160116B/zh not_active Expired - Fee Related
- 2006-03-31 US US11/910,162 patent/US8936809B2/en active Active
- 2006-03-31 PL PL06724133T patent/PL1865924T3/pl unknown
- 2006-03-31 DK DK06724133.1T patent/DK1865924T3/en active
- 2006-03-31 CA CA2602776A patent/CA2602776C/en not_active Expired - Lifetime
-
2007
- 2007-09-03 IL IL185690A patent/IL185690A0/en active IP Right Grant
- 2007-09-19 ZA ZA2007/08066A patent/ZA200708066B/en unknown
- 2007-10-30 NO NO20075490A patent/NO338679B1/no unknown
-
2012
- 2012-11-27 JP JP2012258603A patent/JP2013067639A/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA2602776A1 (en) | 2006-10-05 |
| US20080286205A1 (en) | 2008-11-20 |
| CA2602776C (en) | 2013-10-22 |
| RU2404747C2 (ru) | 2010-11-27 |
| KR101380402B1 (ko) | 2014-04-02 |
| JP2008534546A (ja) | 2008-08-28 |
| ES2557988T3 (es) | 2016-02-01 |
| HUE026158T2 (en) | 2016-05-30 |
| RU2007140243A (ru) | 2009-05-10 |
| CN101160116A (zh) | 2008-04-09 |
| WO2006103112A2 (en) | 2006-10-05 |
| EP1865924B1 (en) | 2015-12-09 |
| WO2006103112A3 (en) | 2006-12-21 |
| PL1865924T3 (pl) | 2016-06-30 |
| KR20140014294A (ko) | 2014-02-05 |
| ZA200708066B (en) | 2016-07-27 |
| CN101160116B (zh) | 2011-12-07 |
| IL185690A0 (en) | 2008-01-06 |
| US8936809B2 (en) | 2015-01-20 |
| JP2013067639A (ja) | 2013-04-18 |
| EP1865924A2 (en) | 2007-12-19 |
| MX2007011908A (es) | 2008-02-07 |
| AU2006228675A1 (en) | 2006-10-05 |
| JP5635231B2 (ja) | 2014-12-03 |
| KR20080002776A (ko) | 2008-01-04 |
| NO338679B1 (no) | 2016-09-26 |
| AU2006228675B2 (en) | 2012-05-17 |
| DK1865924T3 (en) | 2016-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20075490L (no) | Fremgangsmate for behandling av prostatasykdommer basert pa lokal avlevering av aktive substanser | |
| MX2009003372A (es) | Formas de dosificacion de pelicula no mucoadhesiva. | |
| MX341883B (es) | Composicion farmaceutica para el tratamiento y prevencion de canceres. | |
| DK1970059T3 (da) | Lægemiddel med calciumdobesilat til behandling og profylakse af senelidelser | |
| EA201070740A1 (ru) | Способ лечения перелома кости антителами против склеростина | |
| MX2010002498A (es) | Metodos para tratar o prevenir la infeccion del tracto respiratorio que comprende la administracion de colecalciferol. | |
| MX2009002314A (es) | Composiciones farmaceuticas que comprenden hgh para suministro oral. | |
| CY1108217T1 (el) | Μεθοδος χορηγησης βουπρενορφινης για τη θεραπεια της καταθλιψης | |
| WO2006014159A3 (en) | Methods of using regenerative cells in the treatment of musculoskeletal disorders | |
| NZ598370A (en) | Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units | |
| WO2009122252A3 (en) | Dental composition for treating peri-imlantitis | |
| MX2019015733A (es) | Formulacion de melatonina oralmente disoluble con agente acidificante que produce melatonina soluble en saliva. | |
| NO20060498L (no) | Metode for a promotere benvekst | |
| MY151230A (en) | Novel method | |
| NZ598702A (en) | A micro-rna family that modulates fibrosis and uses thereof | |
| EA201790382A1 (ru) | Способы лечения периимплантита | |
| EA201170784A1 (ru) | Гранулы тамсулозина для фиксированной комбинации | |
| TW200420290A (en) | Methods for the treatment, prevention and management of macular degeneration | |
| ATE310509T1 (de) | Methode zur behandlung eines analgesiebedürftigen patienten | |
| EP4442315A3 (en) | Lta4h inhibitor for the treatment or prevention of hidradenitis suppurativa | |
| DE50100833D1 (de) | Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen | |
| BRPI0610780A2 (pt) | formulação farmacéutica em tablete desintegrante, e, métodos para tratar um paciente em necessidade de tratamento com olanzapina, e para produzir a formulação farmacêutica em tablete | |
| NZ594154A (en) | Transdermal administration of buprenorphine for preoperative treatment of post operative pain | |
| AR039162A1 (es) | Formulaciones de venlafaxina de liberacion extendida | |
| BR0209613A (pt) | Composição para tratamento de dor em um mamìfero, e, método para redução ou eliminação de probabilidade de viciamento de um analgésico em um hospedeiro |